Review
Immunology
Anqi Ren, Xiqin Tong, Na Xu, Tongcun Zhang, Fuling Zhou, Haichuan Zhu
Summary: T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive hematological malignancy with high relapse rates and poor prognosis. Current guidelines do not recommend specific treatments, and allogeneic stem cell transplant is the only curative therapy with potential risks. Recent trials have shown success in treating hematologic malignancies with immunotherapies such as monoclonal antibodies, checkpoint inhibitors, and CAR T therapies. However, developing CAR T immunotherapy for T-ALL is challenging due to potential risks of fratricide, T-cell aplasia, immunosuppression, and product contamination.
Review
Oncology
Maryam Akhoundi, Mahsa Mohammadi, Seyedeh Saeideh Sahraei, Mohsen Sheykhhasan, Nashmin Fayazi
Summary: CAR T cell therapy has shown great potential in treating hematologic malignancies, but faces challenges in treating solid tumors, including treatment-related toxicity and specificity. In order to enhance the specificity and overcome immunosuppression, strategies to establish a balance between toxicity and activity of CAR T cells are essential for optimizing efficacy.
Review
Immunology
Long Chen, Fukun Chen, Huatao Niu, Jindan Li, Yongzhu Pu, Conghui Yang, Yue Wang, Rong Huang, Ke Li, Yujie Lei, Yunchao Huang
Summary: CAR-T cell therapy is a novel immunotherapy strategy that has been successfully used against both hematological tumors and solid tumors. Despite some challenges, CAR-T cell treatment still holds great promise.
FRONTIERS IN IMMUNOLOGY
(2022)
Review
Oncology
Grace Guzman, Megan R. Reed, Kevin Bielamowicz, Brian Koss, Analiz Rodriguez
Summary: This review discusses the challenges and opportunities in using chimeric antigen receptor (CAR)-T cell therapy for solid tumors, as well as the development of therapies for pediatric solid tumors. The success of CAR-T cell treatment for hematological malignancies has not been observed in solid tumors due to the hostile tumor microenvironment and heterogeneity. Combinatorial techniques are being developed to overcome these limitations, but further testing is needed. Preliminary results of clinical trials using GD2 and HER2 CAR-T cells are encouraging, but replication on a larger scale is necessary. CAR-T cell application in solid tumors remains challenging, with ongoing clinical trials for pediatric solid tumors showing promising early results but indicating the need for modification to prevent tumor recurrence.
CURRENT ONCOLOGY REPORTS
(2023)
Review
Oncology
Ran Chen, Lei Chen, Chaoqun Wang, Hua Zhu, Lijuan Gu, Yuntao Li, Xiaoxing Xiong, Gang Chen, Zhihong Jian
Summary: This paper discusses the limitations and challenges of CAR-T cell therapy in solid tumors, introduces the latest therapeutic strategies and management decisions to overcome these obstacles, aiming to facilitate the widespread use of CAR-T immunotherapy.
FRONTIERS IN ONCOLOGY
(2023)
Review
Biochemistry & Molecular Biology
Han Yang, Yufang Liu, Longqing Chen, Juanjuan Zhao, Mengmeng Guo, Xu Zhao, Zhenke Wen, Zhixu He, Chao Chen, Lin Xu
Summary: Lung cancer is a prevalent and deadly disease, with limited treatment options, especially for advanced stage patients. However, recent advances in miRNA-based therapies show potential in improving prognosis and overcoming drug resistance. Clinical trials have demonstrated promising outcomes for siRNA and miRNA-based therapies. This review discusses the current state of miRNA-based therapies in lung cancer treatment and their challenges, offering new ideas for the development of novel lung cancer therapies.
Review
Pharmacology & Pharmacy
Benjamin H. Jenkins, Josephine F. Buckingham, Christopher J. Hanley, Gareth J. Thomas
Summary: Cancer-associated fibroblasts (CAFs) are common cells in the tumor microenvironment with diverse tumor-promoting functions. Precise characterization of CAFs and the development of therapeutic strategies are of great importance.
PHARMACOLOGY & THERAPEUTICS
(2022)
Review
Immunology
Aifen Lin, Wei-Hua Yan
Summary: As a new immune checkpoint inhibitor, HLA-G can drive immune suppression and promote tumor growth through signaling pathways. However, challenges such as HLA-G isoform diversity and lack of specific antibodies may affect the efficacy of HLA-G-targeted solid cancer immunotherapy.
FRONTIERS IN IMMUNOLOGY
(2021)
Review
Immunology
Bolin Wang, Jinli Pei, Shengnan Xu, Jie Liu, Jinming Yu
Summary: mRNA cancer vaccines offer high specificity, better efficacy, and fewer side effects compared to traditional treatments, making them a promising approach to cancer immunotherapy. However, the development of these vaccines faces challenges such as tumor heterogeneity, an immunosuppressive tumor microenvironment, and practical obstacles. Recent advances from preclinical studies and clinical trials provide insights into identifying and overcoming these obstacles.
FRONTIERS IN IMMUNOLOGY
(2023)
Review
Oncology
Xinyu Zhang, Xinsheng Cai, Chaoguang Yan
Summary: The combination of radiotherapy and immunotherapy shows promise in the treatment of esophageal cancer and can trigger a systemic anti-tumor immune response.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2023)
Review
Pharmacology & Pharmacy
Hassan Dana, Ghanbar Mahmoodi Chalbatani, Seyed Amir Jalali, Hamid Reza Mirzaei, Stephan A. Grupp, Eloah Rabello Suarez, Catarina Raposo, Thomas J. Webster
Summary: New approaches in cancer immunotherapy, such as checkpoint inhibitors for solid tumors and CAR-T cell therapy for hematologic malignancies, have shown promising results. While CAR-T products have demonstrated powerful effects against B cell cancers, challenges exist in using them for solid tumors.
ACTA PHARMACEUTICA SINICA B
(2021)
Review
Oncology
Melanie Herpels, Jun Ishihara, Anguraj Sadanandam
Summary: Pancreatic ductal adenocarcinoma (PDAC) is a common and aggressive type of pancreatic cancer with low survival rates. Immunotherapeutic agents have been tested against PDACs, but chemotherapy remains the main treatment due to its higher success rates. The complex tumor microenvironment and low mutational burden are the main factors contributing to the low success of immunotherapy. This review provides an overview of the immunotherapies tested in PDAC clinical trials, their limitations, and discusses the potential for personalized PDAC immunotherapy based on the classification of heterogenous PDACs.
JOURNAL OF PATHOLOGY
(2023)
Review
Immunology
Hassan Dianat-Moghadam, Reza Nedaeinia, Mohsen Keshavarz, Mehdi Azizi, Mohammad Kazemi, Rasoul Salehi
Summary: Angiogenesis is a characteristic of cancer biology, and current therapies targeting tumor vasculature have limitations. By combining immunotherapy and nanocarriers, the efficacy of antiangiogenic agents could be improved while reducing the dosage of chemotherapy drugs. Furthermore, the combination of immunotherapies and nano-based delivery systems can extend the window of vascular normalization and overcome the challenges of antiangiogenic agents in treatment.
FRONTIERS IN IMMUNOLOGY
(2023)
Review
Cell & Tissue Engineering
Faroogh Marofi, Roza Motavalli, Vladimir A. Safonov, Lakshmi Thangavelu, Alexei Valerievich Yumashev, Markov Alexander, Navid Shomali, Max Stanley Chartrand, Yashwant Pathak, Mostafa Jarahian, Sepideh Izadi, Ali Hassanzadeh, Naghmeh Shirafkan, Safa Tahmasebi, Farhad Motavalli Khiavi
Summary: CAR T cells have shown significant advancements in treating blood disorders, but face challenges in solid tumor therapy due to issues with recognition, trafficking, and survival within the tumor. Efforts to overcome these challenges, including addressing the immunosuppressive tumor microenvironment, show promise in reducing T cell exhaustion and improving therapeutic outcomes in non-hematologic malignancies.
STEM CELL RESEARCH & THERAPY
(2021)
Review
Oncology
Nuria Mulet-Margalef, Jenniffer Linares, Jordi Badia-Ramentol, Mireya Jimeno, Carolina Sanz Monte, Jose Luis Manzano Mozo, Alexandre Calon
Summary: About 5-15% of colorectal cancers have deficiencies in mismatch repair machinery and high microsatellite instability (dMMR/MSI-H), rendering the tumor immune microenvironment more susceptible to immunotherapy. While immunomodulating drugs have improved treatment for dMMR/MSI-H CRC patients, there is a significant portion that shows resistance due to unknown molecular traits. This review discusses the current understanding of dMMR/MSI-H CRC and its therapeutic implications, as well as efforts to identify resistance mechanisms and predictive biomarkers.
Article
Immunology
Jun Cui, Cheng Chen, Xiao Zhou, Wenju Shan, Yuhong Jian, Panpan Li, Yang Sun, Wei Yi
Summary: Bone marrow mesenchymal stem cells (BMSCs) are a promising therapy for sepsis, but metabolic syndromes threaten their effectiveness. This study investigated the potential of small extracellular vesicles from high-fat diet BMSCs in sepsis-induced liver-heart axis injury.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2024)
Article
Immunology
Binbin Zhu, Angyang Cao, Chunqu Chen, Weijian Zhou, Wenjun Luo, Yu Gui, Qinwen Wang, Zhipeng Xu, Jianhua Wang
Summary: GM6001 alleviates postoperative cognitive deficits and neuroinflammation, preserves blood-brain barrier integrity, and rescues aquaporin-4 mislocalization. MMP-9 inhibition plays a dual role in cognitive protection through direct anti-neuroinflammatory effects and regulation of aquaporin-4 membrane distribution.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2024)
Article
Immunology
Anika Sood, Valencia Fernandes, Kumari Preeti, Shruti Rajan, Dharmendra Kumar Khatri, Shashi Bala Singh
Summary: S1PR2 inhibitor improves cognitive function and skews microglia toward anti-inflammatory phenotype in type 2 diabetic mice, promising to be a potential therapy for neuroinflammation.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2024)
Article
Immunology
Haochun Guo, Ran Yu, Haijun Zhang, Wanpeng Wang
Summary: Radiation therapy is an effective treatment for thoracic malignancies, but it can cause radiation-induced lung injury (RILI), including radiation pneumonitis (RP) and radiation pulmonary fibrosis (RPF). The damage to normal lung cells during radiation treatment leads to a pulmonary inflammatory response, resulting in RP and RPF.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2024)
Article
Immunology
Guanghui Wang, Haotian Zheng, Yunzhi Xiang, Yadong Wang, Kai Wang, Xiaoyang Ren, Jiajun Du
Summary: This study identified a T-cell synthetic driver-associated prognostic model that accurately predicted prognosis and effectiveness of immunotherapy in LUAD patients. It also highlighted the role of LDHA in promoting tumor cell proliferation, invasion, and resistance to treatment, as well as its involvement in immune escape within the tumor microenvironment. These findings provide a promising new therapeutic strategy for LUAD.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2024)
Article
Immunology
Bowen Wei, Aihua Wang, Wei Liu, Qingyun Yue, Yihua Fan, Bin Xue, Siwei Wang
Summary: This study systematically analyzed the association between pSS and cuproptosis, established a predictive model based on 5 genes, explored the pathogenic mechanisms and novel therapeutic strategies for pSS, and identified EED, CBL, and NFU1 as potential targets for treatment.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2024)
Article
Immunology
Nusrit Iqbal Andrabi, Aminur R. Sarkar, Syed Assim Haq, Diljeet Kumar, Dilpreet Kour, Diksha Saroch, Sanket Kumar Shukla, Ajay Kumar, Asha Bhagat, Asif Ali, Gurleen Kour, Zabeer Ahmed
Summary: Koenimbine and its novel semi-synthetic derivative 1G demonstrate significant anti-inflammatory effects by downregulating the nuclear factor kappa-B (NF-kappa B) signaling pathway.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2024)
Article
Immunology
Jing-Mei Lu, Xiang Xu, Fumie Aosai, Ming-Yue Zhang, Lian-Xun Piao
Summary: This study found that arctiin can improve allergic acute liver injury caused by T.g.HSP70 by inhibiting TLR4 signaling and reducing the production of inflammatory mediators.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2024)
Article
Immunology
Minxuan Xu, Fang Shi, Yongshen Gao, Shumei Han, Chensuo Huang, Qinsheng Hou, Xiaoweng Wen, Bengshi Wang, Zhenyu Zhu, Lei Zou, Mingxin Xiong, Wei Dong, Jun Tan
Summary: There is a growing body of research highlighting the involvement of metabolic imbalance and the inflammatory response in the advancement of colitis. This study recognizes arabinose as a significant protector of the intestinal mucosal barrier, reducing damage to the intestines. In addition, lower levels of arabinose in the bloodstream are associated with a higher severity of inflammatory bowel disease and colorectal cancer.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2024)
Article
Immunology
Yueqing Han, Haoxin Song, Yanshan Li, Rongxin Li, Ling Chen, Bo Gao, Yijun Chen, Shuzhen Wang
Summary: The combination of tetracycline antibiotics, demeclocycline (D), chlortetracycline (C), and minocycline (M), showed therapeutic potential against liver fibrosis by inhibiting the activation of hepatic stellate cells and the MAPK signaling. This study suggests that tetracyclines may be repurposed for the treatment of liver fibrosis.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2024)
Article
Immunology
Yu Li, Hailing Liu, Danwen Zhao, Danjie Zhang
Summary: Chronic stress can lead to lung injury, with the spleen playing a crucial role. This study found that the spleen contributes to chronic restraint stress-induced lung injury, and splenic CD11b+ cells may be an important factor in this process.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2024)
Article
Immunology
Yingqian Mi, Mengyan Tang, Qiong Wu, Yinan Wang, Qihui Liu, Pei Zhu, Xiaoyang Xue, Yuntong Liu, Xinyu Chai, Yuyang Hou, Dongmei Yan
Summary: BCG therapy can induce macrophage polarization to the M1 type, and NMAAP1 plays a crucial role in this process by regulating glycolysis and HIF-1α expression. This promotes the antitumor effect of macrophages.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2024)
Article
Immunology
Xiaosheng Liu, Tingxia Lv, Xiuxia Li, Jing Xue, Ling Lin, Lianfeng Lu, Xiaodi Li, Yang Yang, Yuanni Wu, Qiang Wei, Wei Cao, Taisheng Li
Summary: LLDT-8 exhibits notable efficacy in alleviating immune activation in both an in vivo animal model and in vitro human cell experiments, suggesting its potential as a drug for managing systemic immune activation associated with SIV/HIV infection.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2024)
Article
Immunology
Honghong Yu, Qi Li, Huimin Zhu, Chang Liu, Weiwei Chen, Lingyun Sun
Summary: The activation of the inflammasome plays a critical role in the pathogenesis of systemic lupus erythematosus (SLE), and mesenchymal stem cells (MSC) have been shown to alleviate SLE by suppressing inflammasome activation. This study found that the NLRP3 inflammasome was activated in macrophages from SLE patients and mice, and its activation correlated with disease activity. After MSC transplantation, the severity of SLE was reduced, and NLRP3 inflammasome activation was inhibited. These findings suggest that MSC suppress inflammasome activation and provide a potential therapeutic target for SLE.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2024)
Article
Immunology
Wei Zhou, Dan Zeng, Shunan Liu, Yunxia Huang, Fenglin Lv, Weikang Zhou
Summary: This study found that inhibiting HDAC3 can protect the skin from atopic dermatitis by activating the Nrf2 transcription to upregulate Nrf2/HO-1 signaling pathway activity.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2024)